{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-128212","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2024-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.444602+00:00","generated_at":"2026-05-29T03:26:49.467138+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Esperion closes $150M term loan and $210M convertible debt exchange to refinance 2025 notes","bullets":["Entered $150M senior secured term loan at 9.75% cash / 11.75% PIK, due Dec 2029, with minimum liquidity covenant of $50M.","Exchanged ~$210.1M of 4% 2025 notes for $57.5M in new 5.75% notes due 2030 and $153.4M cash; ~$42.5M raised via subscription for new notes.","New notes due 2030 have a conversion rate of 326.7974 shares/$1,000 (approx $3.06/share) and are redeemable from Dec 2027 at 130% threshold.","Proceeds from term loan and subscription will fund cash portion of exchange and general corporate purposes.","After closing, ~$54.9M of 2025 notes remain outstanding with unchanged terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-128212","json":"https://secwatch.observer/filing/0001104659-24-128212.json","markdown":"https://secwatch.observer/filing/0001104659-24-128212.md","text":"https://secwatch.observer/filing/0001104659-24-128212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000110465924128212/0001104659-24-128212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000110465924128212/tm2430949d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:26:49.467138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}